Citigroup Inc. decreased its holdings in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) by 32.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 59,211 shares of the company’s stock after selling 28,808 shares during the period. Citigroup Inc. owned approximately 0.14% of Neoleukin Therapeutics worth $547,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Royal Bank of Canada raised its holdings in Neoleukin Therapeutics by 14.6% in the first quarter. Royal Bank of Canada now owns 9,483 shares of the company’s stock valued at $117,000 after buying an additional 1,209 shares during the period. Millennium Management LLC raised its holdings in Neoleukin Therapeutics by 2.4% in the first quarter. Millennium Management LLC now owns 146,349 shares of the company’s stock valued at $1,802,000 after buying an additional 3,451 shares during the period. Alliancebernstein L.P. raised its stake in shares of Neoleukin Therapeutics by 18.9% during the second quarter. Alliancebernstein L.P. now owns 26,400 shares of the company’s stock valued at $244,000 after purchasing an additional 4,200 shares during the period. Personal CFO Solutions LLC raised its stake in shares of Neoleukin Therapeutics by 26.7% during the second quarter. Personal CFO Solutions LLC now owns 23,710 shares of the company’s stock valued at $219,000 after purchasing an additional 5,000 shares during the period. Finally, Swiss National Bank raised its stake in shares of Neoleukin Therapeutics by 11.8% during the second quarter. Swiss National Bank now owns 73,900 shares of the company’s stock valued at $682,000 after purchasing an additional 7,800 shares during the period. Hedge funds and other institutional investors own 63.57% of the company’s stock.
A number of analysts have recently issued reports on NLTX shares. Zacks Investment Research lowered shares of Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Neoleukin Therapeutics in a research note on Monday, August 9th.
Neoleukin Therapeutics (NASDAQ:NLTX) last released its quarterly earnings results on Thursday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). On average, research analysts forecast that Neoleukin Therapeutics, Inc. will post -1.13 EPS for the current fiscal year.
In related news, CEO Jonathan G. Drachman purchased 100,000 shares of the firm’s stock in a transaction dated Tuesday, August 24th. The stock was acquired at an average price of $6.11 per share, with a total value of $611,000.00. Following the completion of the transaction, the chief executive officer now owns 2,348,686 shares of the company’s stock, valued at $14,350,471.46. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.90% of the stock is currently owned by company insiders.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Want to see what other hedge funds are holding NLTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neoleukin Therapeutics, Inc. (NASDAQ:NLTX).
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.